Healthcare entity
Every one of those 1 sits in a single category, regulation. Of the tracked stories, 1 of 1 also mention Catherine Hanaway, the most common co-covered peer. Source depth averages 2 original sources per story, versus 5.1 across the same-window beat baseline.
Last mentioned: Mar 13, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, regulation. Of the tracked stories, 1 of 1 also mention Catherine Hanaway, the most common co-covered peer. Source depth averages 2 original sources per story, versus 5.1 across the same-window beat baseline. At 8, the average consequence score sits above the same-window beat average of 6.1. DOJ appears in 1 tracked Healthcare story from March 13, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering DOJ. Shared-story counts are live from our verified record — not editorial picks.
DOJ Missouri Filing
DOJ quietly asks the Missouri court to pause proceedings pending FDA review.
Legislative Action
Sen. Josh Hawley introduces a Senate bill to outright ban the abortion pill.
Louisiana Precedent
DOJ unsuccessfully asks Louisiana to pause its separate anti-abortion lawsuit.
Amended Complaint
AG Catherine Hanaway adds claims that mail-order drugs are dangerous without in-person visits.
Lawsuit Filed
Missouri, Kansas, and Idaho file suit against the FDA over mifepristone regulations.
The U.S. Department of Justice has requested a federal court in Missouri to pause or dismiss a lawsuit targeting the FDA's approval of mifepristone, citing an ongoing internal agency review. This move reflects a strategic effort by the administration to manage high-stakes litigation over medication abortion and telehealth access ahead of the 2026 midterms.
DOJ is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
